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PROPOSITIONS 
 
belonging to the thesis 
 




1. The hypertension produced by the VEGFR inhibitor sunitinib is not due to reduced NO 
bioavailability but the result of increased endothelin (this thesis). 
 
2. CYP 2C9 metabolites exert a vasoconstrictor influence in the coronary circulation (this 
thesis). 
 
3. The vascular interaction between PDE5 and ET is highly tissue specific (this thesis). 
 
4. Up4A is a novel and potent vasodilator in the coronary microcirculation (this thesis). 
 
5. The purinergic receptors and endothelial signaling involved in Up4A-mediated coronary 
vasodilation are markedly altered in a variety of cardiovascular disease states, even when 
the overall vasodilator response to Up4A is maintained (this thesis). 
 
6. ETA receptor blockade is a potentially attractive adjuvant therapy in the treatment of 
breast cancer (Fischgrabe et al., Curr Clin Pharmacol 2008; this thesis). 
 
7. The role of a proximal coronary artery obstruction in the pathogenesis of ischemic heart 
disease is overestimated (Marzilli et al., J Am Coll Cardiol 2012).  
 
8. An optimal combination therapy regimen for patients with pulmonary hypertension is 
questionable and should be customized for each individual patient (Buckley, Int J Clin 
Pract Suppl 2013). 
 
9. Juvenile hypertension can be attributed to alterations in purinergic signaling (Jankowski 
et al., Arterioscler Thromb Vasc Biol 2007). 
 
10. Up4A may act by amplifying the biological effects of VEGF (Jankowski et al., J Mol Med 
2013). 
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